Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Aquestive Therapeutics, Inc. (AQST)
USD3.89
-0.15 (-3.72%)
US NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
Address
30 Technology Drive 7059
Warren, NJ, US
Warren, NJ, US
CEO
Daniel Barber
Website
aquestive.com
IPO
2018-07-25
CIK 1398733 ISIN US03843E1047
Description
Aquestive Therapeutics, Inc. is a pharmaceutical company focused on discovering, developing, and commercializing products to address significant unmet medical needs across both the United States and international markets. The company's commercialized portfolio includes: Sympazan, an oral soluble film formulation of clobazam for individuals with Lennox-Gastaut syndrome. Suboxone, a sublingual film containing buprenorphine and naloxone, indicated for the treatment of opioid dependence. Zuplenz, an oral soluble film of ondansetron, used to manage nausea and vomiting associated with chemotherapy and post-operative recovery. Azstarys, a once-daily medication for attention deficit hyperactivity disorder. Aquestive maintains a robust proprietary pipeline of drug candidates. These include: Libervant, a buccal soluble film formulation of diazepam currently in development for the treatment of seizures. Exservan, an oral soluble film of riluzole, aimed at treating amyotrophic lateral sclerosis (ALS). Within its complex molecule pipeline, the company is advancing: AQST-108, a sublingual film designed to deliver systemic epinephrine for conditions other than anaphylaxis. AQST-305, a sublingual film formulation of octreotide for managing acromegaly. AQST-109, an orally administered epinephrine product candidate intended for the emergency treatment of severe allergic reactions, including anaphylaxis. Furthermore, Aquestive Therapeutics played a role in the development of KYNMOBI, a sublingual film formulation of apomorphine, used to address episodic "off" periods in patients with Parkinson's disease. Established in 2004, Aquestive Therapeutics, Inc. is headquartered in Warren, New Jersey.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD3.89
-0.15 (-3.72%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
1.45
Float Shares
95.37M
Free Float %
96.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.72% | -2.82% | -1.43% | +13.15% | -22.08% | -36.07% | +80.35% | +92.09% | +25.53% | -74.27% | -74.27% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (10 ratings, all time)
Buy
Price Targets & DCF
Current price
3.89
Low
6.00
+54.2%
Consensus
9.00
+131.4%
Median
9.00
+131.4%
High
12.00
+208.5%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 7 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 3 |
10.00
+157.1%
|
| All Time | 9 |
9.44
+142.7%
|
Quality scores
Altman Z-Score
-3.17
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-22.6% Q1'26: +65.7% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-49.0% Q1'26: +70.8% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-170.5% Q1'26: -102.9% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-159.5% Q1'26: +0.0% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+40.6% Q1'26: +28.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-1.86× Q1'26: -2.59× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 Rev. Ana. 5 EPS Ana. |
Dec 2027 6 Rev. Ana. 4 EPS Ana. |
Dec 2028 4 Rev. Ana. 3 EPS Ana. |
Dec 2029 3 Rev. Ana. 1 EPS Ana. |
Dec 2030 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
67.43M
est: 67.16M (+0.4%)
|
52.61M
est: 52.04M (+1.1%)
|
45.85M
est: 44.91M (+2.1%)
|
50.83M
est: 49.10M (+3.5%)
|
47.68M
est: 47.40M (+0.6%)
|
50.58M
est: 58.36M (-13.3%)
|
57.56M
est: 58.81M (-2.1%)
|
44.55M
est: 44.80M (-0.6%)
|
48.07M
45.47M – 50.25M
+7.3% YoY
|
68.36M
64.05M – 75.91M
+42.2% YoY
|
97.71M
86.99M – 121.24M
+42.9% YoY
|
165.52M
147.37M – 205.38M
+69.4% YoY
|
249.00M
221.70M – 308.97M
+50.4% YoY
|
| EBITDA |
-50.33M
est: -40.44M (-24.4%)
|
-53.88M
est: -31.33M (-72.0%)
|
-39.15M
est: -27.04M (-44.8%)
|
-45.11M
est: -29.57M (-52.6%)
|
-39.58M
est: -28.54M (-38.7%)
|
1.18M
est: -36.84M (+103.2%)
|
-26.62M
est: -37.13M (+28.3%)
|
-70.49M
est: -28.29M (-149.2%)
|
-30.35M
-31.73M – -28.71M
-7.3% YoY
|
-43.16M
-47.92M – -40.44M
-42.2% YoY
|
-61.69M
-76.54M – -54.92M
-42.9% YoY
|
-104.50M
-129.66M – -93.04M
-69.4% YoY
|
-157.20M
-195.06M – -139.96M
-50.4% YoY
|
| EBIT |
-53.67M
est: -43.48M (-23.4%)
|
-56.93M
est: -33.69M (-69.0%)
|
-42.76M
est: -29.07M (-47.1%)
|
-48.08M
est: -31.79M (-51.3%)
|
-41.97M
est: -30.69M (-36.8%)
|
-163.0K
est: -38.57M (+99.6%)
|
-27.33M
est: -38.86M (+29.7%)
|
-71.05M
est: -29.61M (-140.0%)
|
-31.77M
-33.21M – -30.05M
-7.3% YoY
|
-45.17M
-50.16M – -42.33M
-42.2% YoY
|
-64.57M
-80.12M – -57.49M
-42.9% YoY
|
-109.38M
-135.72M – -97.38M
-69.4% YoY
|
-164.55M
-204.17M – -146.50M
-50.4% YoY
|
| Net Income |
-61.38M
est: -115.56M (+46.9%)
|
-66.25M
est: -211.61M (+68.7%)
|
-55.78M
est: -133.04M (+58.1%)
|
-70.54M
est: -132.17M (+46.6%)
|
-54.41M
est: -91.40M (+40.5%)
|
-7.87M
est: -45.92M (+82.9%)
|
-44.14M
est: -53.21M (+17.1%)
|
-83.78M
est: -74.89M (-11.9%)
|
-61.96M
-64.49M – -45.89M
+17.3% YoY
|
-55.35M
-75.27M – -28.74M
+10.7% YoY
|
-52.79M
-55.10M – -11.81M
+4.6% YoY
|
-3.05M
-4.00M – -2.61M
+94.2% YoY
|
23.17M
19.87M – 30.43M
+860.0% YoY
|
| SGA |
72.26M
est: 65.54M (+10.3%)
|
64.34M
est: 50.78M (+26.7%)
|
55.89M
est: 43.83M (+27.5%)
|
53.48M
est: 47.92M (+11.6%)
|
52.88M
est: 46.26M (+14.3%)
|
31.75M
est: 63.65M (-50.1%)
|
50.18M
est: 64.14M (-21.8%)
|
79.85M
est: 48.86M (+63.4%)
|
52.43M
49.60M – 54.80M
+7.3% YoY
|
74.55M
69.85M – 82.78M
+42.2% YoY
|
106.56M
94.88M – 132.23M
+42.9% YoY
|
180.51M
160.72M – 223.99M
+69.4% YoY
|
271.56M
241.78M – 336.97M
+50.4% YoY
|
| EPS |
-2.96
est: -1.33 (-122.1%)
|
-2.87
est: -2.44 (-17.6%)
|
-1.66
est: -1.53 (-8.2%)
|
-1.85
est: -1.52 (-21.4%)
|
-1.12
est: -1.05 (-7.1%)
|
-0.13
est: -0.35 (+62.5%)
|
-0.51
est: -0.44 (-16.9%)
|
-0.76
est: -0.62 (-22.8%)
|
-0.47
-0.53 – -0.38
+24.4% YoY
|
-0.47
-0.62 – -0.24
-0.7% YoY
|
-0.32
-0.45 – -0.10
+32.1% YoY
|
-0.03
-0.03 – -0.02
+92.2% YoY
|
0.19
0.16 – 0.25
+860.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-45.05M
OE per share TTM
-0.40
Owner's Yield
-8.90%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
18.4%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
86
Total invested
56.19M
Insider transactions (90d)
6
Beneficial owners (>5%)
26
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | (1) BlackRock, Inc. | 5.82M | 6.40% | 5.74M | — | 5.82M | — | HC | Delaware | 2024-11-08 | ↗ |
| 2 | Koh, Bong | 5.56M | 6.50% | — | 5.56M | — | 5.56M | IN | United States | 2024-04-01 | ↗ |
| 3 | Shah, Nimish | 5.56M | 6.50% | — | 5.56M | — | 5.56M | IN | United States | 2024-04-01 | ↗ |
| 4 | VHCP Co-Investment Holdings III, LLC | 5.56M | 6.50% | — | 5.56M | — | 5.56M | OO | Delaware | 2024-04-01 | ↗ |
| 5 | VHCP Management EG, LLC | 5.56M | 6.50% | — | 5.56M | — | 5.56M | OO | Delaware | 2024-04-01 | ↗ |
| 6 | VHCP Management III, LLC | 5.56M | 6.50% | — | 5.56M | — | 5.56M | OO | Delaware | 2024-04-01 | ↗ |
| 7 | Venrock Healthcare Capital Partners EG, L.P. | 5.56M | 6.50% | — | 5.56M | — | 5.56M | PN | Delaware | 2024-04-01 | ↗ |
| 8 | Venrock Healthcare Capital Partners III, L.P. | 5.56M | 6.50% | — | 5.56M | — | 5.56M | PN | Delaware | 2024-04-01 | ↗ |
| 9 | MonoLine RX II, L.P. | 4.03M | 11.00% | 4.03M | — | — | — | PN | — | 2021-02-09 | ↗ |
| 10 | Armistice Capital, LLC | 3.92M | 5.88% | — | 3.92M | — | — | IA, OO | Delaware | 2024-02-14 | ↗ |
| 11 | Steven Boyd | 3.92M | 5.88% | — | 3.92M | — | — | HC, IN | Delaware | 2024-02-14 | ↗ |
| 12 | MonoLine Rx III, L.P. | 2.76M | 11.00% | 2.76M | — | 2.76M | — | PN | — | 2021-02-09 | ↗ |
| 13 | 10 | 2.25M | 7.00% | — | 2.25M | — | 2.25M | IN | Delaware | 2020-02-14 | ↗ |
| 14 | 7.0% | 2.25M | 7.00% | — | 2.25M | — | 2.25M | CO | Delaware | 2020-02-14 | ↗ |
| 15 | MRX Partners, LLC | 2.25M | 11.00% | 2.25M | — | — | — | OO | — | 2021-02-09 | ↗ |
| 16 | MonoLine Rx, L.P. | 2.21M | 11.00% | 2.21M | — | 2.21M | — | PN | — | 2021-02-09 | ↗ |
| 17 | 8.5% | 2.11M | 8.50% | — | 2.11M | — | 2.11M | CO | Delaware | 2019-02-14 | ↗ |
| 18 | Madryn Asset Management, LP | 1.53M | 4.20% | 1.53M | — | 1.53M | — | IA | Delaware | 2020-12-01 | ↗ |
| 19 | Madryn Health Advisors, LP | 1.53M | 4.20% | 1.53M | — | 1.53M | — | PN | Delaware | 2020-12-01 | ↗ |
| 20 | Joseph Edelman | 1.39M | 4.10% | — | 1.39M | — | 1.39M | IN | Delaware | 2021-02-16 | ↗ |
| 21 | Perceptive Advisors LLC | 1.39M | 4.10% | — | 1.39M | — | 1.39M | IA | Delaware | 2021-02-16 | ↗ |
| 22 | Perceptive Life Sciences Master Fund, Ltd. | 1.39M | 4.10% | — | 1.39M | — | 1.39M | CO | Delaware | 2021-02-16 | ↗ |
| 23 | Madryn Health Partners (Cayman Master), LP | 964.4K | 2.60% | 964.4K | — | 964.4K | — | PN | Delaware | 2020-12-01 | ↗ |
| 24 | Madryn Health Partners, LP | 566.4K | 1.50% | 566.4K | — | 566.4K | — | PN | Delaware | 2020-12-01 | ↗ |
| 25 | MonoLine Partners, L.P. | 165.0K | 11.00% | 165.0K | — | 165.0K | — | PN | — | 2021-02-09 | ↗ |
| 26 | MonoSol Rx Genpar, L.P. | 87.5K | 11.00% | 87.5K | — | 87.5K | — | PN | — | 2021-02-09 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
86
-103 vs prev Q
New positions
21
Closed positions
119
Increased
48
Reduced
18
Put/Call ratio
0.29
Calls held
66.5K
Puts held
19.0K
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BRATTON CAPITAL MANAGEMENT, L.P. | 9.81M +— (+0.0%) | 63.38M +8.5M (+15.6%) | 8.87% -1.006 pp | 100.00% +0.000 pp | USD6.30 +2.5% | 29 qtrs — |
| 2 | BLACKROCK, INC. | 7.78M +1.2M (+19.2%) | 50.23M +13.8M (+37.7%) | 7.03% +0.461 pp | 0.00% +0.000 pp | USD5.07 +27.4% | 6 qtrs — |
| 3 | RTW INVESTMENTS, LP | 6.25M +— (+0.0%) | 40.38M +5.4M (+15.6%) | 5.65% -0.641 pp | 0.40% -0.026 pp | USD5.59 +15.6% | 2 qtrs — |
| 4 | VANGUARD GROUP INC | 5.89M +230.2K (+4.1%) | 38.06M +6.4M (+20.3%) | 5.33% -0.372 pp | 0.00% +0.000 pp | USD4.50 +43.6% | 30 qtrs — |
| 5 | ECOR1 CAPITAL, LLC | 2.63M +— (+0.0%) | 16.96M +2.3M (+15.6%) | 2.37% -0.269 pp | 0.77% +0.065 pp | USD5.59 +15.6% | 2 qtrs — |
| 6 | SAMSARA BIOCAPITAL, LLC | 2.50M +— (+0.0%) | 16.15M +2.2M (+15.6%) | 2.26% -0.256 pp | 1.67% -0.158 pp | USD5.59 +15.6% | 2 qtrs — |
| 7 | STATE STREET CORP | 2.46M +860.6K (+53.7%) | 15.91M +7.0M (+77.6%) | 2.23% +0.614 pp | 0.00% +0.000 pp | USD4.58 +41.0% | 23 qtrs — |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 2.37M +280.1K (+13.4%) | 15.30M +3.6M (+31.1%) | 2.14% +0.039 pp | 0.00% +0.000 pp | USD3.45 +87.2% | 30 qtrs — |
| 9 | FEDERATED HERMES, INC. | 2.03M +1.2M (+159.4%) | 13.13M +8.8M (+199.7%) | 1.84% +1.049 pp | 0.02% +0.014 pp | USD6.12 +5.6% | 2 qtrs — |
| 10 | MORGAN STANLEY | 1.76M +348.6K (+24.7%) | 11.36M +3.5M (+44.1%) | 1.59% +0.171 pp | 0.00% +0.000 pp | USD3.68 +75.5% | 30 qtrs — |
| 11 | MILLENNIUM MANAGEMENT LLC | 1.54M +246.0K (+19.1%) | 9.92M +2.7M (+37.6%) | 1.39% +0.090 pp | 0.00% +0.001 pp | USD3.80 +70.0% | 29 qtrs — |
| 12 | BANK OF AMERICA CORP /DE/ | 1.21M -14.5K (-1.2%) | 7.80M +969.3K (+14.2%) | 1.09% -0.138 pp | 0.00% +0.000 pp | USD3.19 +102.5% | 9 qtrs — |
| 13 | WELLS FARGO & COMPANY/MN | 1.19M +1.1M (+804.6%) | 7.68M +6.9M (+945.4%) | 1.07% +0.943 pp | 0.00% +0.001 pp | USD6.18 +4.5% | 30 qtrs — |
| 14 | BNP PARIBAS ARBITRAGE, SNC | 1.17M +1.2M (+6,233.4%) | 7.57M +7.5M (+7,219.1%) | 1.06% +1.041 pp | 0.00% +0.003 pp | USD6.43 +0.5% | 10 qtrs — |
| 15 | JANNEY MONTGOMERY SCOTT LLC | 1.09M -6.6K (-0.6%) | 7.06M +914.0K (+14.9%) | 0.99% -0.119 pp | 0.02% +0.002 pp | USD3.29 +96.4% | 8 qtrs — |
| 16 | COMMONWEALTH EQUITY SERVICES, LLC | 1.02M -38.9K (-3.7%) | 6.59M +669.9K (+11.3%) | 0.92% -0.144 pp | 0.01% +0.001 pp | USD5.59 +15.6% | 2 qtrs — |
| 17 | HRT FINANCIAL LP | 995.0K +434.8K (+77.6%) | 6.43M +3.3M (+105.3%) | 0.90% +0.336 pp | 0.02% +0.009 pp | USD5.97 +8.2% | 5 qtrs — |
| 18 | SIO CAPITAL MANAGEMENT, LLC | 993.1K -505.0K (-33.7%) | 6.42M -2.0M (-23.4%) | 0.90% -0.610 pp | 1.01% -1.110 pp | USD4.04 +59.9% | 4 qtrs — |
| 19 | BALYASNY ASSET MANAGEMENT L.P. | 970.9K +970.9K (+100.0%) | 6.27M +6.3M (+100.0%) | 0.88% +0.878 pp | 0.01% +0.008 pp | USD6.46 +0.0% | 1 qtrs NEW |
| 20 | D. E. SHAW & CO., INC. | 941.2K +915.7K (+3,591.0%) | 6.08M +5.9M (+4,165.4%) | 0.85% +0.825 pp | 0.00% +0.003 pp | USD6.38 +1.3% | 8 qtrs — |
| 21 | GOLDMAN SACHS GROUP INC | 909.1K +513.9K (+130.1%) | 5.87M +3.7M (+165.9%) | 0.82% +0.424 pp | 0.00% +0.001 pp | USD5.30 +21.9% | 11 qtrs — |
| 22 | ABRDN PLC | 809.2K +184.2K (+29.5%) | 5.23M +1.7M (+49.6%) | 0.73% +0.103 pp | 0.01% +0.003 pp | USD5.79 +11.6% | 2 qtrs — |
| 23 | PERCEPTIVE ADVISORS LLC | 747.2K -3.0M (-80.1%) | 4.83M -16.2M (-77.0%) | 0.68% -3.110 pp | 0.09% -0.521 pp | USD4.02 +60.7% | 4 qtrs — |
| 24 | NORTHERN TRUST CORP | 742.8K +59.9K (+8.8%) | 4.80M +981.2K (+25.7%) | 0.67% -0.016 pp | 0.00% +0.000 pp | USD4.44 +45.5% | 30 qtrs — |
| 25 | WASATCH ADVISORS LP | 681.2K -43.0K (-5.9%) | 4.40M +352.1K (+8.7%) | 0.62% -0.113 pp | 0.03% +0.004 pp | USD5.59 +15.6% | 2 qtrs — |
| 26 | CITADEL ADVISORS LLC | 570.9K -197.5K (-25.7%) | 3.69M -607.3K (-14.1%) | 0.52% -0.257 pp | 0.00% 0.000 pp | USD5.32 +21.4% | 24 qtrs — |
| 27 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 554.9K +398.4K (+254.6%) | 3.58M +2.7M (+309.8%) | 0.50% +0.344 pp | 0.00% +0.000 pp | USD6.08 +6.3% | 11 qtrs — |
| 28 | BLUE OWL CAPITAL HOLDINGS LP | 525.0K -725.0K (-58.0%) | 3.39M -3.6M (-51.5%) | 0.47% -0.784 pp | 0.25% -1.915 pp | USD4.28 +50.9% | 8 qtrs — |
| 29 | TREXQUANT INVESTMENT LP | 523.3K +523.3K (+100.0%) | 3.38M +3.4M (+100.0%) | 0.47% +0.473 pp | 0.03% +0.030 pp | USD6.46 +0.0% | 1 qtrs NEW |
| 30 | JANE STREET GROUP, LLC | 512.2K +438.3K (+592.6%) | 3.31M +2.9M (+700.4%) | 0.46% +0.389 pp | 0.00% +0.000 pp | USD6.04 +7.0% | 9 qtrs — |
| 31 | IKARIAN CAPITAL, LLC | 500.0K +500.0K (+100.0%) | 3.23M +3.2M (+100.0%) | 0.45% +0.452 pp | 0.25% +0.252 pp | USD6.46 +0.0% | 1 qtrs NEW |
| 32 | BRACEBRIDGE CAPITAL, LLC | 459.2K +— (+0.0%) | 2.97M +399.5K (+15.6%) | 0.42% -0.047 pp | 0.10% -0.040 pp | USD5.67 +13.9% | 25 qtrs — |
| 33 | RENAISSANCE TECHNOLOGIES LLC | 414.4K +327.4K (+376.3%) | 2.68M +2.2M (+450.5%) | 0.37% +0.287 pp | 0.00% +0.004 pp | USD6.28 +2.9% | 2 qtrs — |
| 34 | TWO SIGMA INVESTMENTS, LP | 381.1K +381.1K (+100.0%) | 2.46M +2.5M (+100.0%) | 0.34% +0.345 pp | 0.00% +0.004 pp | USD6.46 +0.0% | 11 qtrs — |
| 35 | JPMORGAN CHASE & CO | 379.4K -94.2K (-19.9%) | 2.45M -196.3K (-7.4%) | 0.34% -0.134 pp | 0.00% +0.000 pp | USD3.35 +92.8% | 11 qtrs — |
| 36 | DAFNA CAPITAL MANAGEMENT LLC | 375.9K -136.7K (-26.7%) | 2.43M -437.0K (-15.2%) | 0.34% -0.176 pp | 0.56% -0.144 pp | USD5.15 +25.4% | 8 qtrs — |
| 37 | STIFEL FINANCIAL CORP | 369.7K +3.3K (+0.9%) | 2.39M +340.1K (+16.6%) | 0.33% -0.035 pp | 0.00% +0.000 pp | USD3.71 +74.1% | 8 qtrs — |
| 38 | NUVEEN, LLC | 364.0K -180.6K (-33.2%) | 2.35M -692.9K (-22.8%) | 0.33% -0.219 pp | 0.00% 0.000 pp | USD4.60 +40.4% | 4 qtrs — |
| 39 | EVERSTAR ASSET MANAGEMENT, LLC | 344.8K -23.5K (-6.4%) | 2.23M +168.7K (+8.2%) | 0.31% -0.059 pp | 1.19% +0.027 pp | USD3.81 +69.6% | 6 qtrs — |
| 40 | BARCLAYS PLC | 340.8K +241.5K (+243.2%) | 2.20M +1.7M (+345.2%) | 0.31% +0.208 pp | 0.00% +0.000 pp | USD5.68 +13.7% | 7 qtrs — |
| 41 | DIADEMA PARTNERS LP | 337.7K +337.7K (+100.0%) | 2.18M +2.2M (+100.0%) | 0.31% +0.305 pp | 0.38% +0.376 pp | USD6.46 +0.0% | 1 qtrs NEW |
| 42 | TWO SIGMA ADVISERS, LP | 332.4K +332.4K (+100.0%) | 2.15M +2.1M (+100.0%) | 0.30% +0.301 pp | 0.00% +0.004 pp | USD6.46 +0.0% | 25 qtrs — |
| 43 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 301.5K +47.4K (+18.6%) | 1.95M +527.0K (+37.1%) | 0.27% +0.017 pp | 0.00% +0.000 pp | USD3.33 +94.0% | 11 qtrs — |
| 44 | UBS GROUP AG | 296.4K -202.6K (-40.6%) | 1.92M -874.6K (-31.4%) | 0.27% -0.234 pp | 0.00% 0.000 pp | USD4.19 +54.2% | 9 qtrs — |
| 45 | WALLEYE CAPITAL LLC | 287.8K -217.5K (-43.0%) | 1.86M -965.2K (-34.2%) | 0.26% -0.248 pp | 0.01% -0.005 pp | USD4.48 +44.2% | 4 qtrs — |
| 46 | WELLINGTON MANAGEMENT GROUP LLP | 271.0K -14.8K (-5.2%) | 1.75M +153.0K (+9.6%) | 0.25% -0.043 pp | 0.00% +0.000 pp | USD4.65 +38.9% | 6 qtrs — |
| 47 | BANK OF NEW YORK MELLON CORP | 269.8K +62.6K (+30.2%) | 1.74M +584.6K (+50.5%) | 0.24% +0.035 pp | 0.00% +0.000 pp | USD3.69 +75.1% | 23 qtrs — |
| 48 | ADAR1 CAPITAL MANAGEMENT, LLC | 254.0K +254.0K (+100.0%) | 1.64M +1.6M (+100.0%) | 0.23% +0.230 pp | 0.12% +0.121 pp | USD6.46 +0.0% | 1 qtrs NEW |
| 49 | JUMP FINANCIAL, LLC | 246.8K +226.2K (+1,098.4%) | 1.59M +1.5M (+1,284.9%) | 0.22% +0.203 pp | 0.02% +0.018 pp | USD6.39 +1.1% | 2 qtrs — |
| 50 | LATASH INVESTMENTS, LLC | 243.1K +— (+0.0%) | 1.57M +211.5K (+15.6%) | 0.22% -0.025 pp | 1.05% +0.065 pp | USD3.97 +62.7% | 19 qtrs — |
| 51 | JANUS HENDERSON GROUP PLC | 226.7K +226.7K (+100.0%) | 1.46M +1.5M (+100.0%) | 0.21% +0.205 pp | 0.00% +0.001 pp | USD6.46 +0.0% | 1 qtrs NEW |
| 52 | RUSSELL INVESTMENTS GROUP, LTD. | 209.4K +46.0K (+28.2%) | 1.35M +439.6K (+48.1%) | 0.19% +0.025 pp | 0.00% +0.000 pp | USD4.95 +30.5% | 6 qtrs — |
| 53 | SWISS NATIONAL BANK | 202.7K +202.7K (+100.0%) | 1.31M +1.3M (+100.0%) | 0.18% +0.183 pp | 0.00% +0.001 pp | USD6.46 +0.0% | 1 qtrs NEW |
| 54 | LMR PARTNERS LLP | 200.0K +200.0K (+100.0%) | 1.29M +1.3M (+100.0%) | 0.18% +0.181 pp | 0.00% +0.002 pp | USD6.46 +0.0% | 1 qtrs NEW |
| 55 | SEI INVESTMENTS CO | 198.0K +198.0K (+100.0%) | 1.28M +1.3M (+100.0%) | 0.18% +0.179 pp | 0.00% +0.001 pp | USD6.46 +0.0% | 1 qtrs NEW |
| 56 | VOLORIDGE INVESTMENT MANAGEMENT, LLC | 194.1K +194.1K (+100.0%) | 1.25M +1.3M (+100.0%) | 0.18% +0.176 pp | 0.00% +0.004 pp | USD6.46 +0.0% | 1 qtrs NEW |
| 57 | STATE OF WISCONSIN INVESTMENT BOARD | 181.5K +35.5K (+24.3%) | 1.17M +356.3K (+43.6%) | 0.16% +0.017 pp | 0.00% +0.001 pp | USD5.76 +12.2% | 2 qtrs — |
| 58 | VERITION FUND MANAGEMENT LLC | 160.2K +160.2K (+100.0%) | 1.03M +1.0M (+100.0%) | 0.14% +0.145 pp | 0.00% +0.004 pp | USD6.46 +0.0% | 1 qtrs NEW |
| 59 | EAM INVESTORS, LLC | 155.1K +2.7K (+1.8%) | 1.00M +150.1K (+17.6%) | 0.14% -0.013 pp | 0.11% +0.014 pp | USD5.61 +15.2% | 2 qtrs — |
| 60 | CREATIVE PLANNING | 147.0K +2.3K (+1.6%) | 949.4K +140.8K (+17.4%) | 0.13% -0.013 pp | 0.00% +0.000 pp | USD4.30 +50.2% | 8 qtrs — |
| 61 | BOOTHBAY FUND MANAGEMENT, LLC | 137.5K +137.5K (+100.0%) | 888.3K +888.3K (+100.0%) | 0.12% +0.124 pp | 0.01% +0.013 pp | USD6.46 +0.0% | 1 qtrs NEW |
| 62 | RHUMBLINE ADVISERS | 133.5K -931.0 (-0.7%) | 862.7K +111.0K (+14.8%) | 0.12% -0.015 pp | 0.00% +0.000 pp | USD2.80 +130.7% | 7 qtrs — |
| 63 | DIAMETRIC CAPITAL, LP | 128.5K -10.6K (-7.6%) | 830.0K +52.5K (+6.8%) | 0.12% -0.024 pp | 0.22% -0.066 pp | USD3.31 +95.2% | 8 qtrs — |
| 64 | NUMERAI GP LLC | 122.1K +122.1K (+100.0%) | 788.9K +788.9K (+100.0%) | 0.11% +0.110 pp | 0.10% +0.095 pp | USD6.46 +0.0% | 1 qtrs NEW |
| 65 | UBS ASSET MANAGEMENT AMERICAS INC | 120.3K +120.3K (+100.0%) | 776.8K +776.8K (+100.0%) | 0.11% +0.109 pp | 0.00% +0.000 pp | USD6.46 +0.0% | 1 qtrs NEW |
| 66 | PENN CAPITAL MANAGEMENT COMPANY, LLC | 115.9K +23.0K (+24.8%) | 748.9K +229.6K (+44.2%) | 0.10% +0.011 pp | 0.06% +0.020 pp | USD3.74 +72.7% | 4 qtrs — |
| 67 | CAPTION MANAGEMENT, LLC | 115.9K +65.9K (+131.8%) | 748.7K +469.2K (+167.9%) | 0.10% +0.055 pp | 0.01% +0.003 pp | USD6.08 +6.3% | 2 qtrs — |
| 68 | LPL FINANCIAL LLC | 102.4K +12.5K (+13.9%) | 661.4K +159.0K (+31.6%) | 0.09% +0.002 pp | 0.00% +0.000 pp | USD3.96 +63.1% | 3 qtrs — |
| 69 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 100.8K +95.4K (+1,772.2%) | 651.3K +621.2K (+2,063.6%) | 0.09% +0.086 pp | 0.00% +0.001 pp | USD6.25 +3.4% | 7 qtrs — |
| 70 | FINANCIAL ENGINES ADVISORS L.L.C. | 97.5K +1.7K (+1.8%) | 629.7K +94.5K (+17.7%) | 0.09% -0.008 pp | 0.00% +0.000 pp | USD3.37 +91.7% | 3 qtrs — |
| 71 | ALLIANCEBERNSTEIN L.P. | 92.0K +3.9K (+4.4%) | 594.3K +101.8K (+20.7%) | 0.08% -0.006 pp | 0.00% +0.000 pp | USD3.06 +111.1% | 7 qtrs — |
| 72 | HIGHTOWER ADVISORS, LLC | 91.5K -9.5K (-9.4%) | 591.3K +26.5K (+4.7%) | 0.08% -0.019 pp | 0.00% +0.000 pp | USD2.61 +147.5% | 20 qtrs — |
| 73 | DEUTSCHE BANK AG\ | 83.4K +8.6K (+11.5%) | 539.0K +120.8K (+28.9%) | 0.08% +0.000 pp | 0.00% +0.000 pp | USD4.65 +38.9% | 6 qtrs — |
| 74 | LEGAL & GENERAL GROUP PLC | 81.9K +73.6K (+885.4%) | 529.0K +482.6K (+1,038.7%) | 0.07% +0.066 pp | 0.00% +0.000 pp | USD6.07 +6.4% | 7 qtrs — |
| 75 | ADVISOR GROUP HOLDINGS, INC. | 79.7K -66.2K (-45.4%) | 514.9K -303.5K (-37.1%) | 0.07% -0.075 pp | 0.00% 0.000 pp | USD3.77 +71.4% | 8 qtrs — |
| 76 | STRATOS WEALTH PARTNERS, LTD. | 73.7K +652.0 (+0.9%) | 475.8K +67.7K (+16.6%) | 0.07% -0.007 pp | 0.01% +0.001 pp | USD5.18 +24.7% | 6 qtrs — |
| 77 | LOS ANGELES CAPITAL MANAGEMENT LLC | 68.2K +68.2K (+100.0%) | 454.2K +454.2K (+100.0%) | 0.06% +0.062 pp | 0.00% +0.002 pp | USD6.46 +0.0% | 1 qtrs NEW |
| 78 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 67.7K +33.9K (+100.0%) | 437.6K +248.2K (+131.1%) | 0.06% +0.027 pp | 0.00% +0.004 pp | USD6.02 +7.3% | 2 qtrs — |
| 79 | ZURCHER KANTONALBANK (ZURICH CANTONALBANK) | 65.0K +65.0K (+100.0%) | 420.0K +420.0K (+100.0%) | 0.06% +0.059 pp | 0.00% +0.001 pp | USD6.46 +0.0% | 1 qtrs NEW |
| 80 | INVESCO LTD. | 65.0K +10.9K (+20.2%) | 419.9K +117.6K (+38.9%) | 0.06% +0.004 pp | 0.00% +0.000 pp | USD5.01 +28.9% | 8 qtrs — |
| 81 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 64.9K -2.8K (-4.1%) | 419.3K +40.8K (+10.8%) | 0.06% -0.010 pp | 0.01% +0.001 pp | USD2.90 +122.8% | 28 qtrs — |
| 82 | BANK OF MONTREAL /CAN/ | 64.7K +45.6K (+239.6%) | 417.9K +311.4K (+292.4%) | 0.06% +0.039 pp | 0.00% +0.000 pp | USD5.74 +12.5% | 30 qtrs — |
| 83 | AQR CAPITAL MANAGEMENT LLC | 61.7K +3.9K (+6.8%) | 398.6K +75.7K (+23.4%) | 0.06% -0.002 pp | 0.00% +0.000 pp | USD4.86 +32.9% | 6 qtrs — |
| 84 | VERUS CAPITAL PARTNERS, LLC | 60.8K +27.2K (+81.0%) | 392.8K +204.9K (+109.1%) | 0.06% +0.021 pp | 0.02% +0.011 pp | USD5.98 +8.0% | 2 qtrs — |
| 85 | CORSAIR CAPITAL MANAGEMENT, L.P. | 60.0K +60.0K (+100.0%) | 387.6K +387.6K (+100.0%) | 0.05% +0.054 pp | 0.06% +0.060 pp | USD6.46 +0.0% | 1 qtrs NEW |
| 86 | METLIFE INVESTMENT MANAGEMENT, LLC | 58.2K +9.5K (+19.5%) | 375.7K +103.8K (+38.2%) | 0.05% +0.004 pp | 0.00% +0.001 pp | USD3.99 +61.9% | 7 qtrs — |
| 87 | OCCUDO QUANTITATIVE STRATEGIES LP | 56.5K +56.5K (+100.0%) | 365.3K +365.3K (+100.0%) | 0.05% +0.051 pp | 0.02% +0.025 pp | USD6.46 +0.0% | 1 qtrs NEW |
| 88 | AXQ CAPITAL, LP | 56.4K -12.9K (-18.6%) | 364.1K -22.9K (-5.9%) | 0.05% -0.019 pp | 0.08% -0.066 pp | USD5.59 +15.6% | 2 qtrs — |
| 89 | PRICE T ROWE ASSOCIATES INC /MD/ | 56.0K +10.9K (+24.1%) | 362.0K +109.0K (+43.1%) | 0.05% +0.005 pp | 0.00% +0.000 pp | USD4.71 +37.2% | 6 qtrs — |
| 90 | SUGAR MAPLE ASSET MANAGEMENT, LLC | 54.9K +42.9K (+357.1%) | 354.3K +287.3K (+428.2%) | 0.05% +0.038 pp | 0.24% +0.190 pp | USD5.68 +13.7% | 4 qtrs — |
| 91 | CITIGROUP INC | 51.5K +47.0K (+1,030.5%) | 332.9K +307.4K (+1,206.5%) | 0.05% +0.042 pp | 0.00% +0.000 pp | USD6.25 +3.4% | 9 qtrs — |
| 92 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 48.5K +9.1K (+23.0%) | 313.3K +92.9K (+42.2%) | 0.04% +0.004 pp | 0.00% +0.000 pp | USD5.07 +27.4% | 6 qtrs — |
| 93 | PENBROOK MANAGEMENT LLC | 42.2K -1.4K (-3.3%) | 272.4K +28.7K (+11.8%) | 0.04% -0.006 pp | 0.19% +0.018 pp | USD3.10 +108.4% | 4 qtrs — |
| 94 | HBK SORCE ADVISORY LLC | 42.5K -99.0 (-0.2%) | 174.9K -138.2K (-44.1%) | 0.04% -0.005 pp | 0.00% -0.004 pp | USD1.19 +442.9% | 12 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 61 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Simplify Propel Opportunities ETF SURI | 1.48% | 1.15M | 2.82% |
| 2 | State Street SPDR S&P Pharmaceuticals ETF XPH | 0.74% | 3.49M | 0.35% |
| 3 | Invesco NASDAQ Future Gen 200 ETF QQQS | 0.51% | 112.4K | 0.20% |
| 4 | Federated Hermes MDT Small Cap Core ETF FSCC | 0.23% | 383.1K | 0.51% |
| 5 | Direxion Daily Pharmaceutical & Medical Bull 3X ETF PILL | 0.15% | 35.8K | 1.22% |
| 6 | iShares Micro-Cap ETF IWC | 0.10% | 1.50M | 0.60% |
| 7 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.04% | 164.5K | 0.40% |
| 8 | Invesco Nasdaq Biotechnology ETF IBBQ | 0.04% | 26.5K | 0.19% |
| 9 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.04% | 26.0K | 0.35% |
| 10 | iShares Nasdaq US Biotechnology UCITS ETF BTEC.L | 0.04% | 388.6K | 0.35% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
5
Shares acquired
—
Shares disposed
634.2K
Cash buys
—
Cash sales
—
Net activity
-634,233
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | BRAENDER LORI J | Officer | F-InKind | D | Common Stock | 135,690 | 4.23 | 574.0K | 231,042 | D | ↗ |
| 2026-05-05 | TOTH A ERNEST JR | Officer | F-InKind | D | Common Stock | 92,652 | 4.18 | 387.3K | 283,460 | D | ↗ |
| 2026-05-05 | Jung Cassie | Officer | F-InKind | D | Common Stock | 72,734 | 4.18 | 304.0K | 202,246 | D | ↗ |
| 2026-05-05 | Boyd Peter E. | Officer | F-InKind | D | Common Stock | 56,778 | 4.18 | 237.3K | 281,731 | D | ↗ |
| 2026-05-05 | Barber Daniel | Officer | F-InKind | D | Common Stock | 335,922 | 4.18 | 1.40M | 668,831 | D | ↗ |
| 2026-05-05 | BRAENDER LORI J | Officer | F-InKind | D | Common Stock | 76,147 | 4.18 | 318.3K | 366,732 | D | ↗ |
| 2026-04-02 | Zalewski Thomas A. | Officer | — | — | Common Stock | 0 | 0.00 | — | 0 | D | ↗ |
| 2026-03-10 | TOTH A ERNEST JR | Officer | S-Sale | D | Common Stock | 58,254 | 4.17 | 243.1K | 376,112 | D | ↗ |
| 2026-03-10 | Korczynski Sherry | Officer | S-Sale | D | Common Stock | 15,741 | 4.17 | 65.7K | 241,117 | D | ↗ |
| 2026-03-10 | Jung Cassie | Officer | S-Sale | D | Common Stock | 45,791 | 4.17 | 191.1K | 274,980 | D | ↗ |
| 2026-03-10 | Cioffi Melina | Officer | S-Sale | D | Common Stock | 25,311 | 4.17 | 105.6K | 274,867 | D | ↗ |
| 2026-03-10 | Boyd Peter E. | Officer | S-Sale | D | Common Stock | 29,814 | 4.17 | 124.4K | 338,509 | D | ↗ |
| 2026-03-10 | Barber Daniel | Officer | S-Sale | D | Common Stock | 180,677 | 4.17 | 754.0K | 1,004,753 | D | ↗ |
| 2026-03-10 | BRAENDER LORI J | Officer | S-Sale | D | Common Stock | 40,102 | 4.17 | 167.3K | 442,879 | D | ↗ |
| 2026-03-09 | TOTH A ERNEST JR | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 70,000 | 4.29 | 300.3K | 70,000 | D | ↗ |
| 2026-03-09 | Korczynski Sherry | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 42,500 | 4.29 | 182.3K | 42,500 | D | ↗ |
| 2026-03-09 | Jung Cassie | Officer | A-Award | A | Common Stock | 80,000 | 0.00 | — | 320,771 | D | ↗ |
| 2026-03-09 | Greenhawt Matthew J. | Officer | A-Award | A | Common Stock | 75,000 | 0.00 | — | 75,000 | D | ↗ |
| 2026-03-09 | Davis Matthew W. | Officer | A-Award | A | Common Stock | 50,000 | 0.00 | — | 100,000 | D | ↗ |
| 2026-03-09 | Cioffi Melina | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 75,000 | 4.29 | 321.8K | 75,000 | D | ↗ |
| 2026-03-09 | Boyd Peter E. | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 42,500 | 4.29 | 182.3K | 42,500 | D | ↗ |
| 2026-03-09 | Barber Daniel | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 523,000 | 4.29 | 2.24M | 523,000 | D | ↗ |
| 2026-03-09 | BRAENDER LORI J | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 50,000 | 4.29 | 214.5K | 50,000 | D | ↗ |
| 2026-03-02 | Greenhawt Matthew J. | Officer | — | — | Common Stock | 0 | 0.00 | — | 2,000 | I | ↗ |
| 2025-12-04 | Boyd Peter E. | Officer | A-Award | A | Common Stock | 20,000 | 0.00 | — | 288,323 | D | ↗ |
| 2025-12-02 | Cioffi Melina | Officer | F-InKind | D | Common Stock | 2,083 | 5.93 | 12.4K | 200,178 | D | ↗ |
| 2025-11-10 | Davis Matthew W. | Officer | A-Award | A | Common Stock | 50,000 | 0.00 | — | 50,000 | D | ↗ |
| 2025-11-03 | Davis Matthew W. | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-10-15 | Kraus Carl N | Officer | S-Sale | D | Common Stock | 20,272 | 7.00 | 141.9K | 282,475 | D | ↗ |
| 2025-10-15 | Jung Cassie | Officer | M-Exempt | A | Common Stock | 25,000 | 3.10 | 77.6K | 308,346 | D | ↗ |
| 2025-10-15 | Boyd Peter E. | Officer | S-Sale | D | Common Stock | 10,000 | 7.00 | 70.0K | 268,323 | D | ↗ |
| 2025-09-26 | Boyd Peter E. | Officer | S-Sale | D | Common Stock | 10,000 | 6.30 | 63.0K | 278,323 | D | ↗ |
| 2025-09-26 | Barber Daniel | Director / Officer | S-Sale | D | Common Stock | 91,343 | 6.03 | 551.2K | 923,430 | D | ↗ |
| 2025-09-19 | Barber Daniel | Director / Officer | S-Sale | D | Common Stock | 400 | 6.00 | 2.4K | 1,014,773 | D | ↗ |
| 2025-09-05 | Boyd Peter E. | Officer | S-Sale | D | Common Stock | 15,000 | 5.30 | 79.5K | 288,323 | D | ↗ |
| 2025-09-04 | Jung Cassie | Officer | M-Exempt | D | Non-Qualified Stock Option (right to buy) | 25,000 | 3.15 | 78.8K | 0 | D | ↗ |
| 2025-08-14 | Korczynski Sherry | Officer | A-Award | A | Common Stock | 25,000 | 0.00 | — | 181,858 | D | ↗ |
| 2025-08-09 | Kraus Carl N | Officer | F-InKind | D | Common Stock | 10,819 | 3.90 | 42.2K | 302,747 | D | ↗ |
| 2025-06-11 | Taglietti Marco | Director | A-Award | A | Stock Option (Right to Purchase) | 42,000 | 3.41 | 143.2K | 42,000 | D | ↗ |
| 2025-06-11 | MORRIS TIMOTHY E | Director | A-Award | A | Stock Option (right to purchase) | 42,000 | 3.41 | 143.2K | 42,000 | D | ↗ |
| 2025-06-11 | Krop Julie | Director | A-Award | A | Stock Option (Right to Purchase) | 42,000 | 3.41 | 143.2K | 42,000 | D | ↗ |
| 2025-06-11 | Jenkins Abigail L. | Director | A-Award | D | Non-Qualified Stock Option (right to buy) | 42,000 | 3.41 | 143.2K | 42,000 | D | ↗ |
| 2025-06-11 | Cochran John | Director | A-Award | A | Stock Option (Right to Purchase) | 42,000 | 3.41 | 143.2K | 42,000 | D | ↗ |
| 2025-06-11 | BROWN GREGORY B | Director | A-Award | A | Stock Option (Right to Purchase) | 42,000 | 3.41 | 143.2K | 42,000 | D | ↗ |
| 2025-06-09 | Korczynski Sherry | Officer | F-InKind | D | Common Stock | 2,714 | 3.54 | 9.6K | 156,858 | D | ↗ |
| 2025-05-15 | Cioffi Melina | Officer | A-Award | A | Common Stock | 20,000 | 0.00 | — | 202,261 | D | ↗ |
| 2025-04-25 | Cioffi Melina | Officer | — | — | Common Stock | 0 | 0.00 | — | 182,261 | D | ↗ |
| 2025-03-10 | Wargacki Stephen | Officer | F-InKind | D | Common Stock | 4,572 | 2.54 | 11.6K | 343,552 | D | ↗ |
| 2025-03-10 | Jung Cassie | Officer | F-InKind | D | Common Stock | 2,182 | 2.54 | 5.5K | 295,526 | D | ↗ |
| 2025-03-09 | Wargacki Stephen | Officer | F-InKind | D | Common Stock | 15,431 | 2.65 | 40.9K | 348,124 | D | ↗ |
| 2025-03-09 | TOTH A ERNEST JR | Officer | F-InKind | D | Common Stock | 8,736 | 2.65 | 23.2K | 339,366 | D | ↗ |
| 2025-03-09 | Jung Cassie | Officer | F-InKind | D | Common Stock | 7,997 | 2.65 | 21.2K | 297,708 | D | ↗ |
| 2025-03-09 | Boyd Peter E. | Officer | F-InKind | D | Common Stock | 7,681 | 2.65 | 20.4K | 303,323 | D | ↗ |
| 2025-03-09 | Barber Daniel | Officer | F-InKind | D | Common Stock | 53,998 | 2.65 | 143.1K | 1,015,173 | D | ↗ |
| 2025-03-09 | BRAENDER LORI J | Officer | F-InKind | D | Common Stock | 10,658 | 2.65 | 28.2K | 402,981 | D | ↗ |
| 2025-03-07 | Wargacki Stephen | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 65,000 | 2.65 | 172.3K | 65,000 | D | ↗ |
| 2025-03-07 | TOTH A ERNEST JR | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 60,000 | 2.65 | 159.0K | 60,000 | D | ↗ |
| 2025-03-07 | Kraus Carl N | Officer | A-Award | A | Common Stock | 70,000 | 0.00 | — | 321,681 | D | ↗ |
| 2025-03-07 | Korczynski Sherry | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 35,000 | 2.65 | 92.8K | 35,000 | D | ↗ |
| 2025-03-07 | Jung Cassie | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 40,000 | 2.65 | 106.0K | 40,000 | D | ↗ |
| 2025-03-07 | Boyd Peter E. | Officer | F-InKind | D | Common Stock | 6,624 | 2.65 | 17.6K | 311,004 | D | ↗ |
| 2025-03-07 | Barber Daniel | Officer | F-InKind | D | Common Stock | 29,307 | 2.65 | 77.7K | 1,069,171 | D | ↗ |
| 2025-03-07 | BRAENDER LORI J | Officer | A-Award | A | Common Stock | 110,000 | 0.00 | — | 423,231 | D | ↗ |
| 2024-12-02 | BRATTON DOUGLAS K | 10% Owner | G-Gift | D | Common Stock | 40,000 | 0.00 | — | 199,841 | I | ↗ |
| 2024-11-26 | Jung Cassie | Officer | S-Sale | D | Common Stock | 44 | 4.87 | 214.06 | 0 | I | ↗ |
| 2024-08-09 | Kraus Carl N | Officer | F-InKind | D | Common Stock | 10,819 | 3.43 | 37.1K | 251,681 | — | ↗ |
| 2024-06-20 | Taglietti Marco | Director | A-Award | A | Stock Option (Right to Purchase) | 38,000 | 2.50 | 95.0K | 38,000 | — | ↗ |
| 2024-06-20 | MORRIS TIMOTHY E | Director | A-Award | A | Stock Option (right to purchase) | 38,000 | 2.50 | 95.0K | 38,000 | — | ↗ |
| 2024-06-20 | Krop Julie | Director | A-Award | A | Stock Option (Right to Purchase) | 38,000 | 2.50 | 95.0K | 38,000 | — | ↗ |
| 2024-06-20 | Cochran John | Director | A-Award | A | Stock Option (Right to Purchase) | 38,000 | 2.50 | 95.0K | 38,000 | — | ↗ |
| 2024-06-20 | COSTA SANTO J | Director | A-Award | A | Stock Option (Right to Purchase) | 38,000 | 2.50 | 95.0K | 38,000 | — | ↗ |
| 2024-06-20 | BROWN GREGORY B | Director | A-Award | A | Stock Option (Right to Purchase) | 38,000 | 2.50 | 95.0K | 38,000 | — | ↗ |
| 2024-06-07 | Korczynski Sherry | Officer | A-Award | A | Common Stock | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2024-06-03 | Korczynski Sherry | Officer | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-05-10 | Wargacki Stephen | Officer | A-Award | A | Common Stock | 10,000 | 0.00 | — | 267,963 | — | ↗ |
| 2024-05-10 | Jenkins Abigail L. | Director | A-Award | D | Non-Qualified Stock Option (right to buy) | 57,000 | 3.09 | 176.1K | 57,000 | — | ↗ |
| 2024-04-01 | Jenkins Abigail L. | Director | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-03-15 | Schobel Alexander Mark | Officer | S-Sale | D | Common Stock | 50,000 | 6.00 | 300.0K | 984,476 | — | ↗ |
| 2024-03-10 | Wargacki Stephen | Officer | F-InKind | D | Common Stock | 1,687 | 4.88 | 8.2K | 257,963 | — | ↗ |
| 2024-03-10 | Jung Cassie | Officer | F-InKind | D | Common Stock | 1,132 | 4.88 | 5.5K | 237,754 | — | ↗ |
| 2024-03-09 | Wargacki Stephen | Officer | F-InKind | D | Common Stock | 11,269 | 4.88 | 55.0K | 259,650 | — | ↗ |
| 2024-03-09 | TOTH A ERNEST JR | Officer | F-InKind | D | Common Stock | 11,705 | 4.88 | 57.1K | 248,295 | — | ↗ |
| 2024-03-09 | Schobel Alexander Mark | Officer | F-InKind | D | Common Stock | 5,895 | 4.88 | 28.8K | 1,034,476 | — | ↗ |
| 2024-03-09 | Jung Cassie | Officer | F-InKind | D | Common Stock | 14,120 | 4.88 | 68.9K | 233,066 | D | ↗ |
| 2024-03-09 | Boyd Peter E. | Officer | F-InKind | D | Common Stock | 8,370 | 4.88 | 40.8K | 237,628 | — | ↗ |
| 2024-03-09 | Barber Daniel | Officer | F-InKind | D | Common Stock | 37,938 | 4.88 | 185.1K | 845,364 | — | ↗ |
| 2024-03-09 | BRAENDER LORI J | Officer | F-InKind | D | Common Stock | 10,530 | 4.88 | 51.4K | 313,231 | — | ↗ |
| 2024-03-08 | Schobel Alexander Mark | Officer | S-Sale | D | Common Stock | 25,000 | 5.19 | 129.7K | 1,040,371 | — | ↗ |
| 2024-03-07 | Wargacki Stephen | Officer | A-Award | A | Common Stock | 112,500 | 0.00 | — | 270,919 | — | ↗ |
| 2024-03-07 | TOTH A ERNEST JR | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 60,000 | 5.68 | 340.8K | 60,000 | — | ↗ |
| 2024-03-07 | Schobel Alexander Mark | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 41,250 | 5.68 | 234.3K | 41,250 | — | ↗ |
| 2024-03-07 | Kraus Carl N | Officer | A-Award | A | Common Stock | 112,500 | 0.00 | — | 262,500 | — | ↗ |
| 2024-03-07 | Jung Cassie | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 50,625 | 5.68 | 287.6K | 50,625 | — | ↗ |
| 2024-03-07 | Boyd Peter E. | Officer | A-Award | A | Common Stock | 86,250 | 0.00 | — | 245,998 | — | ↗ |
| 2024-03-07 | Barber Daniel | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 363,900 | 5.68 | 2.07M | 363,900 | — | ↗ |
| 2024-03-07 | BRAENDER LORI J | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 67,500 | 5.68 | 383.4K | 67,500 | — | ↗ |
| 2023-08-09 | Wargacki Stephen | Officer | A-Award | A | Performance Stock Units | 67,500 | 0.00 | — | 67,500 | — | ↗ |
| 2023-08-09 | TOTH A ERNEST JR | Officer | A-Award | A | Performance Stock Units | 70,000 | 0.00 | — | 70,000 | — | ↗ |
| 2023-08-09 | Schobel Alexander Mark | Officer | A-Award | A | Performance Stock Units | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2023-08-09 | Marshall Ken W. | Officer | A-Award | A | Performance Stock Units | 75,000 | 0.00 | — | 75,000 | — | ↗ |
| 2023-08-09 | Kraus Carl N | Officer | A-Award | A | Common Stock | 150,000 | 0.00 | — | 150,000 | — | ↗ |
| 2023-08-09 | Jung Cassie | Officer | A-Award | A | Performance Stock Units | 55,000 | 0.00 | — | 55,000 | — | ↗ |
| 2023-08-09 | Boyd Peter E. | Officer | A-Award | A | Performance Stock Units | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2023-08-09 | Barber Daniel | Officer | A-Award | A | Performance Stock Units | 223,500 | 0.00 | — | 223,500 | — | ↗ |
| 2023-08-09 | BRAENDER LORI J | Officer | A-Award | A | Performance Stock Units | 75,000 | 0.00 | — | 75,000 | — | ↗ |
| 2023-08-05 | Cioffi Melina | Officer | — | — | Employee Stock Option (right to buy) | 25,000 | 0.88 | 22.0K | 0 | D | ↗ |
| 2023-06-26 | Kraus Carl N | Officer | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-06-21 | Taglietti Marco | Director | A-Award | A | Stock Option (Right to Purchase) | 25,000 | 2.02 | 50.5K | 25,000 | — | ↗ |
| 2023-06-21 | MORRIS TIMOTHY E | Director | A-Award | A | Stock Option (right to purchase) | 25,000 | 2.02 | 50.5K | 25,000 | — | ↗ |
| 2023-06-21 | Krop Julie | Director | A-Award | A | Stock Option (Right to Purchase) | 25,000 | 2.02 | 50.5K | 25,000 | — | ↗ |
| 2023-06-21 | Cochran John | Director | A-Award | A | Stock Option (Right to Purchase) | 25,000 | 2.02 | 50.5K | 25,000 | — | ↗ |
| 2023-06-21 | COSTA SANTO J | Director | A-Award | A | Stock Option (Right to Purchase) | 25,000 | 2.02 | 50.5K | 25,000 | — | ↗ |
| 2023-06-21 | BROWN GREGORY B | Director | A-Award | A | Stock Option (Right to Purchase) | 25,000 | 2.02 | 50.5K | 25,000 | — | ↗ |
| 2023-05-05 | Wargacki Stephen | Officer | A-Award | A | Performance Stock Units | 67,500 | 0.00 | — | 67,500 | — | ↗ |
| 2023-05-05 | TOTH A ERNEST JR | Officer | A-Award | A | Performance Stock Units | 70,000 | 0.00 | — | 70,000 | — | ↗ |
| 2023-05-05 | Schobel Alexander Mark | Officer | A-Award | A | Performance Stock Units | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2023-05-05 | Marshall Ken W. | Officer | A-Award | A | Performance Stock Units | 75,000 | 0.00 | — | 75,000 | — | ↗ |
| 2023-05-05 | Jung Cassie | Officer | A-Award | A | Performance Stock Units | 55,000 | 0.00 | — | 55,000 | — | ↗ |
| 2023-05-05 | Boyd Peter E. | Officer | A-Award | A | Performance Stock Units | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2023-05-05 | Barber Daniel | Officer | A-Award | A | Performance Stock Units | 223,500 | 0.00 | — | 223,500 | — | ↗ |
| 2023-05-05 | BRAENDER LORI J | Officer | A-Award | A | Performance Stock Units | 75,000 | 0.00 | — | 75,000 | — | ↗ |
| 2023-03-10 | Wargacki Stephen | Officer | F-InKind | D | Common Stock | 1,981 | 0.79 | 1.6K | 158,419 | — | ↗ |
| 2023-03-10 | Jung Cassie | Officer | F-InKind | D | Common Stock | 1,365 | 0.00 | — | 145,936 | — | ↗ |
| 2023-03-09 | Wargacki Stephen | — | A-Award | A | Common Stock | 135,000 | 0.00 | — | 161,956 | — | ↗ |
| 2023-03-09 | TOTH A ERNEST JR | — | A-Award | A | Common Stock | 140,000 | 0.00 | — | 140,000 | — | ↗ |
| 2023-03-09 | Schobel Alexander Mark | — | A-Award | A | Common Stock | 100,000 | 0.00 | — | 982,871 | — | ↗ |
| 2023-03-09 | Marshall Ken W. | — | A-Award | A | Common Stock | 150,000 | 0.00 | — | 150,000 | — | ↗ |
| 2023-03-09 | Jung Cassie | — | A-Award | A | Common Stock | 110,000 | 0.00 | — | 146,747 | — | ↗ |
| 2023-03-09 | Boyd Peter E. | — | A-Award | A | Common Stock | 100,000 | 0.00 | — | 159,532 | — | ↗ |
| 2023-03-09 | Barber Daniel | — | A-Award | A | Common Stock | 447,000 | 0.00 | — | 640,702 | — | ↗ |
| 2023-03-09 | BRAENDER LORI J | — | A-Award | A | Common Stock | 150,000 | 0.00 | — | 188,761 | — | ↗ |
| 2023-01-01 | Wargacki Stephen | Director | — | D | Common Stock | 0 | 0.00 | — | 26,956 | — | ↗ |
| 2023-01-01 | Jung Cassie | Director | — | I | Common Stock | 0 | 0.00 | — | 2,000 | — | ↗ |
| 2022-11-04 | TOTH A ERNEST JR | Director / Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2022-11-04 | Schobel Alexander Mark | Director / Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2022-11-04 | Marshall Ken W. | Director / Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2022-11-04 | Boyd Peter E. | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-11-04 | BRAENDER LORI J | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2022-09-06 | Truitt Kenneth | — | A-Award | A | Non-Qualified Stock Option (right to buy) | 100,000 | 1.25 | 125.0K | 100,000 | — | ↗ |
| 2022-08-16 | MORRIS TIMOTHY E | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 28,500 | 0.00 | — | 28,500 | — | ↗ |
| 2022-08-05 | Barber Daniel | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2022-06-22 | Taglietti Marco | Director | A-Award | A | Stock Option (Right to Purchase) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-06-22 | Krop Julie | Director | A-Award | A | Stock Option (Right to Purchase) | 25,000 | 0.71 | 17.8K | 25,000 | — | ↗ |
| 2022-06-22 | Cochran John | Director | A-Award | A | Stock Option (Right to Purchase) | 25,000 | 0.71 | 17.8K | 25,000 | — | ↗ |
| 2022-06-22 | COSTA SANTO J | Director | A-Award | A | Stock Option (Right to Purchase) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-06-22 | BROWN GREGORY B | Director | A-Award | A | Stock Option (Right to Purchase) | 25,000 | 0.71 | 17.8K | 25,000 | — | ↗ |
| 2022-06-14 | Boyd Peter E. | Officer | P-Purchase | A | Common Stock | 5,000 | 0.81 | 4.1K | 59,532 | — | ↗ |
| 2022-06-10 | Cioffi Melina | Officer | — | — | Employee Stock Option (right to buy) | 25,000 | 4.07 | 101.8K | 0 | D | ↗ |
| 2022-06-08 | Schobel Alexander Mark | Officer | P-Purchase | A | Warrant (Right to Buy) | 45,871 | 0.96 | 44.0K | 45,871 | — | ↗ |
| 2022-06-08 | Boyd Peter E. | Officer | P-Purchase | A | Common Stock | 2,293 | 0.96 | 2.2K | 54,532 | — | ↗ |
| 2022-06-08 | Barber Daniel | Officer | P-Purchase | A | Warrant (Right to Buy) | 91,743 | 0.13 | 11.9K | 91,743 | — | ↗ |
| 2022-06-08 | BRAENDER LORI J | Officer | P-Purchase | A | Warrant (Right to Buy) | 13,761 | 0.96 | 13.2K | 13,761 | — | ↗ |
| 2022-03-10 | Wood Theresa | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 70,000 | 0.00 | — | 70,000 | — | ↗ |
| 2022-03-10 | TOTH A ERNEST JR | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 70,000 | 0.00 | — | 70,000 | — | ↗ |
| 2022-03-10 | Schobel Alexander Mark | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 75,000 | 2.55 | 191.3K | 75,000 | — | ↗ |
| 2022-03-10 | Marshall Ken W. | Director / Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 80,000 | 0.00 | — | 80,000 | — | ↗ |
| 2022-03-10 | Kendall Keith J | Director / Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 375,000 | 2.55 | 956.3K | 375,000 | — | ↗ |
| 2022-03-10 | Boyd Peter E. | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 70,000 | 0.00 | — | 70,000 | — | ↗ |
| 2022-03-10 | Barber Daniel | Director / Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 225,000 | 0.00 | — | 225,000 | — | ↗ |
| 2022-03-10 | BRAENDER LORI J | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 160,000 | 2.55 | 408.0K | 160,000 | — | ↗ |
| 2021-11-24 | Cioffi Melina | Officer | — | — | Employee Stock Option (right to buy) | 12,500 | 6.62 | 82.8K | 0 | D | ↗ |
| 2021-08-31 | Cioffi Melina | Officer | — | — | Employee Stock Option (right to buy) | 15,000 | 7.86 | 117.9K | 0 | D | ↗ |
| 2021-08-26 | Kendall Keith J | — | G-Gift | D | Common Stock | 1,000 | 0.00 | — | 636,149 | — | ↗ |
| 2021-06-15 | Taglietti Marco | — | A-Award | A | Stock Option (Right to Purchase) | 20,000 | 4.04 | 80.8K | 20,000 | — | ↗ |
| 2021-06-15 | TOTH A ERNEST JR | — | A-Award | A | Stock Option (Right to Purchase) | 120,000 | 4.04 | 484.8K | 120,000 | — | ↗ |
| 2021-06-15 | Scibetta James S | — | A-Award | A | Stock Option (Right to Purchase) | 20,000 | 4.04 | 80.8K | 20,000 | — | ↗ |
| 2021-06-15 | Lurker Nancy | — | A-Award | A | Stock Option (Right to Purchase) | 20,000 | 4.04 | 80.8K | 20,000 | — | ↗ |
| 2021-06-15 | Krop Julie | — | A-Award | A | Stock Option (Right to Purchase) | 20,000 | 4.04 | 80.8K | 20,000 | — | ↗ |
| 2021-06-15 | Cochran John | — | A-Award | A | Stock Option (Right to Purchase) | 20,000 | 4.04 | 80.8K | 20,000 | — | ↗ |
| 2021-06-15 | COSTA SANTO J | — | A-Award | A | Stock Option (Right to Purchase) | 20,000 | 4.04 | 80.8K | 20,000 | — | ↗ |
| 2021-06-15 | BROWN GREGORY B | — | A-Award | A | Stock Option (Right to Purchase) | 20,000 | 4.04 | 80.8K | 20,000 | — | ↗ |
| 2021-05-10 | Cochran John | — | G-Gift | D | Common Stock | 37,500 | 0.00 | — | 99,486 | — | ↗ |
| 2021-03-12 | Cochran John | — | J-Other | A | Common Stock | 23,038 | 0.00 | — | 98,123 | — | ↗ |
| 2021-03-12 | BRATTON DOUGLAS K | — | J-Other | D | Common Stock | 40,404 | 0.00 | — | 47,051 | — | ↗ |
| 2021-03-11 | Wood Theresa | — | A-Award | A | Non-Qualified Stock Option (right to buy) | 27,000 | 5.30 | 143.1K | 27,000 | — | ↗ |
| 2021-03-11 | Taglietti Marco | — | A-Award | A | Non-Qualified Stock Option (right to buy) | 28,500 | 5.30 | 151.1K | 28,500 | — | ↗ |
| 2021-03-11 | TOTH A ERNEST JR | — | A-Award | A | Non-Qualified Stock Option (right to buy) | 2,500 | 5.30 | 13.3K | 2,500 | — | ↗ |
| 2021-03-11 | Schobel Alexander Mark | — | A-Award | A | Non-Qualified Stock Option (right to buy) | 70,000 | 5.30 | 371.0K | 70,000 | — | ↗ |
| 2021-03-11 | Marshall Ken W. | — | A-Award | A | Non-Qualified Stock Option (right to buy) | 40,000 | 5.30 | 212.0K | 40,000 | — | ↗ |
| 2021-03-11 | Krop Julie | — | A-Award | A | Non-Qualified Stock Option (right to buy) | 28,500 | 5.30 | 151.1K | 28,500 | — | ↗ |
| 2021-03-11 | Kendall Keith J | — | A-Award | A | Non-Qualified Stock Option (right to buy) | 250,000 | 5.30 | 1.33M | 250,000 | — | ↗ |
| 2021-03-11 | Boyd Peter E. | — | A-Award | A | Non-Qualified Stock Option (right to buy) | 35,000 | 5.30 | 185.5K | 35,000 | — | ↗ |
| 2021-03-11 | Barber Daniel | — | A-Award | A | Non-Qualified Stock Option (right to buy) | 100,000 | 5.30 | 530.0K | 100,000 | — | ↗ |
| 2021-03-11 | BRAENDER LORI J | — | A-Award | A | Non-Qualified Stock Option (right to buy) | 75,000 | 5.30 | 397.5K | 75,000 | — | ↗ |
| 2021-03-09 | BRATTON DOUGLAS K | — | G-Gift | D | Common Stock | 62,500 | 0.00 | — | 12,585 | — | ↗ |
| 2021-02-10 | Taglietti Marco | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-02-10 | Schobel Alexander Mark | — | S-Sale | D | Common Stock | 23,460 | 6.75 | 158.4K | 837,000 | — | ↗ |
| 2021-02-10 | Krop Julie | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-02-09 | Schobel Alexander Mark | — | S-Sale | D | Common Stock | 11,540 | 6.75 | 77.9K | 860,460 | — | ↗ |
| 2021-02-08 | Schobel Alexander Mark | — | S-Sale | D | Common Stock | 40,792 | 6.50 | 265.1K | 872,000 | — | ↗ |
| 2020-12-31 | TOTH A ERNEST JR | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-12-30 | Kendall Keith J | — | G-Gift | D | Common Stock | 1,000 | 0.00 | — | 637,149 | — | ↗ |
| 2020-08-18 | Maxwell John T. | — | S-Sale | D | Common Stock | 3,000 | 8.00 | 24.0K | 150,614 | — | ↗ |
| 2020-06-30 | Schobel Alexander Mark | — | M-Exempt | A | Common Stock | 333 | 0.00 | — | 912,886 | — | ↗ |
| 2020-06-30 | Kendall Keith J | — | M-Exempt | A | Common Stock | 333 | 0.00 | — | 639,297 | — | ↗ |
| 2020-06-16 | Scibetta James S | — | A-Award | A | Stock Option (Right to Purchase) | 14,000 | 5.30 | 74.2K | 14,000 | — | ↗ |
| 2020-06-16 | Lurker Nancy | — | A-Award | A | Stock Option (Right to Purchase) | 14,000 | 5.30 | 74.2K | 14,000 | — | ↗ |
| 2020-06-16 | Cochran John | — | A-Award | A | Stock Option (Right to Purchase) | 14,000 | 5.30 | 74.2K | 14,000 | — | ↗ |
| 2020-06-16 | COSTA SANTO J | — | A-Award | A | Stock Option (Right to Purchase) | 14,000 | 5.30 | 74.2K | 14,000 | — | ↗ |
| 2020-06-16 | BROWN GREGORY B | — | A-Award | A | Stock Option (Right to Purchase) | 14,000 | 5.30 | 74.2K | 14,000 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-500.4K
Shares Outstanding
99.31M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Daniel Barber President and Chief Executive Officer | 659.9K | — | 1.55M | 877.2K | 409.1K | — | 3.49M | 69.40% | ↗ |
| 2 | 2025 | Lori J. Braender Corporate Secretary, Former Chief Legal Officer and Chief Compliance Officer | 458.0K | — | 524.2K | 129.0K | 237.1K | — | 1.35M | 48.44% | ↗ |
| 3 | 2025 | A. Ernest Toth, Jr. Chief Financial Officer | 442.6K | — | 524.2K | 129.0K | 227.8K | — | 1.32M | 49.35% | ↗ |
| 4 | 2024 | Daniel Barber Chief Executive Officer | 633.4K | — | 1.38M | 1.71M | 435.6K | 28.5K | 4.18M | 73.75% | ↗ |
| 5 | 2024 | Daniel Barber President and Chief Executive Officer | 633.4K | — | 1.38M | 1.71M | 435.6K | 28.5K | 4.18M | 73.75% | ↗ |
| 6 | 2024 | A. Mark Schobel Chief Innovation and Technology Officer* | 367.5K | — | 468.6K | 193.4K | 262.5K | 1.97M | 3.26M | 20.32% | ↗ |
| 7 | 2024 | Lori J. Braender Chief Legal Officer, Chief Compliance Officer and Corporate Secretary | 444.4K | — | 766.8K | 316.5K | 263.9K | 29.4K | 1.82M | 59.49% | ↗ |
| 8 | 2024 | Lori J. Braender Corporate Secretary, Former Chief Legal Officer and Chief Compliance Officer | 439.4K | — | 766.8K | 316.5K | 263.9K | 29.4K | 1.82M | 59.65% | ↗ |
| 9 | 2023 | Daniel Barber Chief Executive Officer | 600.0K | — | 1.43M | — | 355.5K | 27.9K | 2.42M | 59.30% | ↗ |
| 10 | 2023 | Lori J. Braender Chief Legal Officer, Chief Compliance Officer and Corporate Secretary | 417.3K | — | 480.8K | — | 216.8K | 32.0K | 1.15M | 41.92% | ↗ |
| 11 | 2023 | A. Mark Schobel Chief Innovation and Technology Officer* | 350.0K | — | 320.5K | — | 275.6K | 27.9K | 974.1K | 32.90% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Daniel Barber | Chief Executive Officer, President & Director | 1M | male |
| Lori J. Braender BSBA | Corporate Secretary | 695.1K | female |
| A. Ernest Toth Jr. | Senior VP & CFO | 670.4K | male |
| Matthew Greenhawt | Chief Medical Officer | — | — |
| Matthew William Davis | Chief Development Officer | — | — |
| Melina T. Cioffi | Senior Vice President of Regulatory Affairs | — | — |
| Peter E. Boyd | Senior Vice President of Information Technology & Chief People Officer | — | male |
| Robert Charles Arnold | Vice President of Finance, Controller & Assistant Secretary | — | male |
| Sherry Korczynski | Chief Commercial Officer | — | female |
| Thomas A. Zalewski | Chief Legal Officer & Chief Compliance Officer | — | male |
| Cassie Jung | Chief Operating Officer | — | female |
| Gary H. Slatko | Interim Chief Medical Officer | — | — |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AQST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
